Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
18 Maggio 2023 - 10:30PM
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global
biopharmaceutical company developing novel oral small molecule
therapeutics for metabolic and pulmonary diseases, today announced
that the Company will present three scientific posters at the
upcoming 2023 American Thoracic Society (ATS) International
Conference taking place May 19-24, 2023, in Washington, DC.
“These data demonstrate the power of our GPCR
structure-based drug discovery technology across broad therapeutic
areas including cardiopulmonary diseases,” said Raymond Stevens,
Ph.D., Founder and CEO of Structure Therapeutics. “In close
partnership with Schrödinger’s computational capabilities, we
designed and discovered potential best-in-class orally available
novel small molecules against the LPAR1 and APJR receptors which we
are excited to continue to advance.”
Clinical and pre-clinical presentations
include:
Poster presentation (P1059):
Structure Based Discovery and Anti-fibrotic Activity of Novel
Antagonists of Lysophosphatidic Acid Receptor 1 (LPAR1)
- Date: Sunday, May 21, 2023
- Presentation Time: 11:30 a.m. – 1:15 p.m.
ET
- Session (A67): Biomarkers, Mediators, and
Translational Models for ILD
Poster presentation (P207): A
First-in-Human Single/Multiple Ascending Dose Study of ANPA-0073, a
Novel Small Molecule G-protein Biased Apelin Receptor Agonist, in
Healthy Volunteers
- Date: Monday, May 22, 2023
- Presentation Time: 11:30 p.m. – 1:15 p.m.
ET
- Session (B59): Breaking Bad: New Drugs and
Formulations for Pulmonary Hypertension
Poster presentation (P925):
Discovery of G-protein Biased APJ Agonist Small Molecule for
Pulmonary Diseases
- Date: Wednesday, May 24, 2023
- Presentation Time: 12:00 p.m. – 2:00 p.m.
ET
- Session (D108): Cells, Signaling, and
Mediators in Lung Remodeling and Fibrosis
A copy of the presentation materials can be
accessed by visiting the “Presentations” section of the Structure
Therapeutics website after the conclusion of the presentations and
will be archived on the Structure Therapeutics website.
About Structure
TherapeuticsStructure Therapeutics is a leading
clinical-stage biopharmaceutical company focused on discovering and
developing innovative oral treatments for chronic metabolic and
pulmonary conditions with significant unmet medical need. Utilizing
its next generation structure-based drug discovery platform, the
company has established a scientifically-driven, GPCR-targeted
pipeline, featuring two wholly-owned proprietary clinical-stage
small molecule compounds designed to surpass the limitations of
traditional biologic and peptide therapies and be accessible to
more patients around the world. For additional information, please
visit www.structuretx.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements, including, without
limitation, statements concerning the Company’s future plans and
prospects, the Company’s anticipated cash runway, any expectations
regarding the safety or efficacy of GSBR-1290 and other candidates
under development, the ability of GSBR-1290 to treat type 2
diabetes, obesity or related indications, plans with respect to
regulatory submissions, the planned timing of the Company’s
clinical trials, data results and continued development of
GSBR-1290 and expectations regarding an oral development candidate
targeting GLP-1R. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and
similar expressions and their variants, as they relate to the
Company may identify forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Although the Company believes the expectations
reflected in such forward-looking statements are reasonable, the
Company can give no assurance that such expectations will prove to
be correct. Readers are cautioned that actual results, levels of
activity, safety, performance or events and circumstances could
differ materially from those expressed or implied in the Company’s
forward-looking statements due to a variety of risks and
uncertainties, which include, without limitation, risks and
uncertainties related to the Company’s ability to advance
GSBR-1290, LTSE-2578, ANPA-0073 and its other therapeutic
candidates, obtain regulatory approval of and ultimately
commercialize the Company’s therapeutic candidates, the timing and
results of preclinical and clinical trials, the Company’s ability
to fund development activities and achieve development goals, the
impact of the ongoing COVID-19 pandemic, inflation, supply chain
issues, rising interest rates and future bank failures on the
Company’s business, its ability to protect its intellectual
property and other risks and uncertainties described in the
Company’s filings with the Securities and Exchange Commission
(“SEC”), including the Company’s Quarterly Report on Form 10-Q
filed with the SEC on May 11, 2023 and future reports the Company
may file with the SEC from time to time. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. The Company undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made, except as required by law.
Contacts:
Investors:Jun Yoon, Chief
Financial OfficerStructure Therapeutics Inc.ir@structuretx.com
Media:Dan
Budwick1ABDan@1abmedia.com
Grafico Azioni Structure Therapeutics (NASDAQ:GPCR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Structure Therapeutics (NASDAQ:GPCR)
Storico
Da Giu 2023 a Giu 2024